一名葡萄糖-6-磷酸脱氢酶缺乏的患者在接受羟氯喹治疗COVID-19时发生溶血性贫血：病例报告
Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report.
作者信息
Aguilar Jorge, Averbukh Yelena
机构信息
Montefiore Medical Center, Bronx, New York.
出版信息
Perm J. 2020;24. doi: 10.7812/TPP/20.158.
Abstract
INTRODUCTION
The growing coronavirus disease 2019 (COVID-19) pandemic initially led to widespread use of hydroxychloroquine sulfate as an off-label experimental treatment of this disease.
CASE PRESENTATION
Acute hemolytic anemia developed in an African American man with COVID-19-related pneumonia and glucose-6-phosphate dehydrogenase (G6PD) deficiency who completed the standard 5-day experimental course of hydroxychloroquine. Although the trigger leading to our patient's hemolytic sequelae will never be known with certainty, his clinical course suggests that hydroxychloroquine use and/or COVID-19 infection may trigger hemolysis in susceptible patients with G6PD deficiency.
DISCUSSION
This case confirms recent findings that the potential risks of hydroxychloroquine therapy for COVID-19 may outweigh the benefits.
摘要
引言
2019年冠状病毒病（COVID-19）疫情的不断蔓延，最初导致硫酸羟氯喹被广泛用作这种疾病的非标签实验性治疗药物。
病例介绍
一名患有COVID-19相关肺炎且葡萄糖-6-磷酸脱氢酶（G6PD）缺乏的非裔美国男性，在完成了标准的5天羟氯喹实验疗程后，出现了急性溶血性贫血。虽然导致我们这位患者溶血后遗症的确切诱因永远无法确定，但他的临床病程表明，使用羟氯喹和/或感染COVID-19可能会在G6PD缺乏的易感患者中引发溶血。
讨论
该病例证实了近期的研究结果，即羟氯喹治疗COVID-19的潜在风险可能超过其益处。
相似文献
1
2
A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.葡萄糖-6-磷酸脱氢酶缺乏症 COVID-19 患者接受羟氯喹后发生严重溶血的病例报告。
Infect Dis (Lond). 2020 Sep;52(9):659-661. doi: 10.1080/23744235.2020.1774644. Epub 2020 Jun 4.
3
Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review.葡萄糖-6-磷酸脱氢酶缺乏症与羟氯喹在新冠疫情时代：一篇小型综述。
Mol Biol Rep. 2021 Mar;48(3):2973-2978. doi: 10.1007/s11033-021-06234-y. Epub 2021 Feb 23.
4
COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency.COVID-19 感染和羟氯喹治疗导致葡萄糖-6-磷酸脱氢酶缺乏症患者发生严重溶血性危机。
Eur J Haematol. 2020 Sep;105(3):357-359. doi: 10.1111/ejh.13432. Epub 2020 May 7.
5
COVID-19 and hydroxychloroquine side-effects: glucose 6-phosphate dehydrogenase deficiency (G6PD) and acute haemolytic anaemia.新型冠状病毒肺炎与羟氯喹副作用：葡萄糖-6-磷酸脱氢酶缺乏症（G6PD）和急性溶血性贫血
QJM. 2020 Dec 1;113(12):890-891. doi: 10.1093/qjmed/hcaa267.
6
Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?为什么在使用羟氯喹治疗新冠肺炎之前要筛查葡萄糖-6-磷酸脱氢酶缺乏症？
J Pediatr Hematol Oncol. 2021 Jan;43(1):35-36. doi: 10.1097/MPH.0000000000001864.
7
No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency.没有证据表明氯喹或羟氯喹在葡萄糖-6-磷酸脱氢酶缺乏症中会诱发溶血。
Blood Cells Mol Dis. 2020 Nov;85:102484. doi: 10.1016/j.bcmd.2020.102484. Epub 2020 Aug 7.
8
Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a "humanized" G6PD A- mouse model.简要报告：羟氯喹在“人源化”G6PD A- 小鼠模型中不会诱导溶血性贫血或器官损伤。
PLoS One. 2020 Oct 2;15(10):e0240266. doi: 10.1371/journal.pone.0240266. eCollection 2020.
9
Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase.羟氯喹使用与葡萄糖-6-磷酸脱氢酶水平低的患者溶血性贫血的相关性。
J Clin Rheumatol. 2022 Jan 1;28(1):e23-e25. doi: 10.1097/RHU.0000000000001571.
10
A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency.一例新冠病毒病患者，患有无症状血红蛋白D地中海贫血和葡萄糖-6-磷酸脱氢酶缺乏症
Am J Case Rep. 2020 Jul 22;21:e925788. doi: 10.12659/AJCR.925788.
引用本文的文献
1
Hematologic Outcomes of COVID-19 Patients with and without G6PD Deficiency: A Comparative Study.伴有和不伴有葡萄糖-6-磷酸脱氢酶（G6PD）缺乏的COVID-19患者的血液学结果：一项比较研究。
Qatar Med J. 2022 Nov 16;2022(4):54. doi: 10.5339/qmj.2022.54. eCollection 2022.
2
Hydroxychloroquine Therapy Led to the Diagnosis of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency in an Elderly Patient with COVID-19 Involvement: A Case Report and Review of the Literature.羟氯喹治疗导致1例合并新型冠状病毒肺炎的老年患者被诊断为葡萄糖-6-磷酸脱氢酶（G6PD）缺乏症：1例病例报告及文献复习
Case Rep Med. 2022 Oct 3;2022:4749424. doi: 10.1155/2022/4749424. eCollection 2022.
3
Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.新型冠状病毒肺炎患者与非新型冠状病毒肺炎患者短期口服氯喹和羟氯喹治疗的安全性：一项系统评价
Pharmaceuticals (Basel). 2022 May 21;15(5):634. doi: 10.3390/ph15050634.
4
Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives.葡萄糖-6-磷酸脱氢酶缺乏症的治疗策略：过去和未来的观点。
Trends Pharmacol Sci. 2021 Oct;42(10):829-844. doi: 10.1016/j.tips.2021.07.002. Epub 2021 Aug 10.
5
The Affinity of Hemoglobin for Oxygen Is Not Altered During COVID-19.新冠病毒感染期间血红蛋白对氧气的亲和力未发生改变。
Front Physiol. 2021 Apr 12;12:578708. doi: 10.3389/fphys.2021.578708. eCollection 2021.
6
The Role of Methemoglobin and Carboxyhemoglobin in COVID-19: A Review.高铁血红蛋白和碳氧血红蛋白在新型冠状病毒肺炎中的作用：综述
J Clin Med. 2020 Dec 25;10(1):50. doi: 10.3390/jcm10010050.
本文引用的文献
1
Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.检查葡萄糖-6-磷酸脱氢酶（G6PDH）缺乏患者中羟氯喹的使用与溶血性贫血。
Arthritis Care Res (Hoboken). 2018 Mar;70(3):481-485. doi: 10.1002/acr.23296. Epub 2018 Feb 9.
2
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.2015年美国风湿病学会类风湿关节炎治疗指南
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Epub 2015 Nov 6.
3
Primaquine: the risks and the benefits.伯氨喹：风险与益处
Malar J. 2014 Nov 3;13:418. doi: 10.1186/1475-2875-13-418.
4
Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.药物与葡萄糖-6-磷酸脱氢酶缺乏：循证综述。
Drug Saf. 2010 Sep 1;33(9):713-26. doi: 10.2165/11536520-000000000-00000.
5
Glucose-6-phosphate dehydrogenase deficiency: correlation between the genotype, biochemistry and phenotype.葡萄糖-6-磷酸脱氢酶缺乏症：基因型、生物化学和表型之间的相关性。
Ann Acad Med Singap. 2008 Dec;37(12 Suppl):81-3.
6
Erythrocyte variants and the nature of their malaria protective effect.红细胞变体及其疟疾保护作用的本质。
Cell Microbiol. 2005 Jun;7(6):753-63. doi: 10.1111/j.1462-5822.2005.00524.x.
7
Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance.伯氨喹敏感性。葡萄糖-6-磷酸脱氢酶缺乏症：一种具有医学和生物学意义的先天性代谢缺陷。
Arch Intern Med. 1962 Feb;109:209-34. doi: 10.1001/archinte.1962.03620140081013.
8
G6PD: population genetics and clinical manifestations.葡萄糖-6-磷酸脱氢酶：群体遗传学与临床表现
Blood Rev. 1996 Mar;10(1):45-52. doi: 10.1016/s0268-960x(96)90019-3.
Zotero 插件